Avanir's AVP-786 meets in Phase III for Alzheimer's agitation

cafead

Administrator
Staff member
  • cafead   Mar 25, 2019 at 10:52: PM
via Avanir said one of two doses of AVP-786 met the primary endpoint of improving agitation symptoms in the Phase III 15-AVP-786-301 trial to treat agitation in patients with Alzheimer's dementia.

article source
 

<